| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(02)09962-2 |
| P698 | PubMed publication ID | 12243915 |
| P2093 | author name string | R Edwards | |
| J Forbes | |||
| A Coates | |||
| M Baum | |||
| J Cuzick | |||
| A Hamed | |||
| T Powles | |||
| A Howell | |||
| S Cawthorn | |||
| IBIS investigators | |||
| P2860 | cites work | Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial | Q28277066 |
| Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study | Q28283241 | ||
| Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group | Q29619251 | ||
| A brief review of the current breast cancer prevention trials and proposals for future trials | Q33959743 | ||
| Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation | Q34191632 | ||
| A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey | Q36423070 | ||
| 'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer | Q38522407 | ||
| Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study | Q41732897 | ||
| Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study | Q42540931 | ||
| Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial | Q44045676 | ||
| Prevention of breast cancer with tamoxifen--an update on the Royal Marsden Hospital pilot programme | Q68426584 | ||
| Tamoxifen and contralateral breast cancer | Q69867231 | ||
| The prevention of breast cancer | Q69874879 | ||
| Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association | Q95721603 | ||
| P433 | issue | 9336 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| P304 | page(s) | 817-824 | |
| P577 | publication date | 2002-09-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial | |
| P478 | volume | 360 |
| Q36357196 | "If I'm better than average, then I'm ok?": Comparative information influences beliefs about risk and benefits |
| Q46098542 | 2'-Hydroxyflavanone: A novel strategy for targeting breast cancer |
| Q49263298 | A comparison of five methods of measuring mammographic density: a case-control study. |
| Q37282240 | A framework for evaluating markers used to select patient treatment |
| Q37352516 | A new approach to menopausal therapy: the tissue selective estrogen complex |
| Q33914381 | A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast |
| Q80635187 | A reconsideration of tamoxifen use for breast cancer |
| Q39500972 | Acceptability and adherence in a chemoprevention trial among women at increased risk for breast cancer attending the Modena Familial Breast and Ovarian Cancer Center (Italy). |
| Q44866777 | Acceptance of tamoxifen chemoprevention by physicians and women at risk |
| Q35585792 | Advances in breast cancer detection and management |
| Q24803990 | Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy |
| Q35705287 | Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysis |
| Q83917287 | American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction |
| Q44659430 | Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial |
| Q35082355 | Anti-oestrogenic chemoprevention of breast cancer-the need to progress |
| Q34932305 | Anti-oestrogenic prevention of breast cancer--the make or break point |
| Q36317263 | Antiangiogenic tetrathiomolybdate protects against Her2/neu-induced breast carcinoma by hypoplastic remodeling of the mammary gland |
| Q57108351 | Antiplatelet Therapy in Breast Cancer Patients Using Hormonal Therapy: Myths, Evidence and Potentialities - Systematic Review |
| Q35612327 | Aromatase inhibitors for chemoprevention |
| Q30249199 | Atypical epithelial hyperplasia of the breast: state of the art. |
| Q30301033 | Atypical hyperplasia of the breast--risk assessment and management options |
| Q37204722 | Australian clinicians and chemoprevention for women at high familial risk for breast cancer |
| Q34878214 | Ayurvedic medicine constituent withaferin a causes G2 and M phase cell cycle arrest in human breast cancer cells |
| Q35023437 | Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older |
| Q35091219 | Benzyl isothiocyanate inhibits epithelial-mesenchymal transition in cultured and xenografted human breast cancer cells |
| Q36949369 | Benzyl isothiocyanate targets mitochondrial respiratory chain to trigger reactive oxygen species-dependent apoptosis in human breast cancer cells |
| Q36769051 | Best surgical prophylaxis--risk-reducing mastectomy for women at high personal risk of breast cancer |
| Q37788248 | Biological considerations and clinical applications of new HER2-targeted agents |
| Q37785215 | Breast Cancer Prevention Trials: Large and Small Trials |
| Q57134756 | Breast cancer chemoprevention |
| Q27693259 | Breast cancer chemoprevention: old and new approaches |
| Q27692587 | Breast cancer chemoprevention: progress and controversy |
| Q35101733 | Breast cancer in women after treatment for Hodgkin's disease |
| Q51182331 | Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene. |
| Q42836293 | Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. |
| Q35586829 | Breast cancer prevention—clinical trials strategies involving aromatase inhibitors |
| Q57266500 | Breast cancer risk assessment in 8,824 women attending a family history evaluation and screening programme |
| Q44233018 | Breast cancer: aromatase inhibitors take on tamoxifen |
| Q37598890 | Breast cancer: beyond the cutting edge |
| Q35204980 | Breast cancer: occurrence, risk factors and hormone metabolism |
| Q36216690 | Breast cancer: the challenges facing surgeons in the next two decades. |
| Q44529008 | Breast-cancer prevention: is the risk-benefit ratio in favour of tamoxifen? |
| Q44487660 | Can breast cancer be chemoprevented in 2003? |
| Q37719958 | Casticin induces breast cancer cell apoptosis by inhibiting the expression of forkhead box protein M1. |
| Q39555908 | Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells |
| Q57133081 | Chemoprevention of breast cancer |
| Q83227175 | Chemoprevention of breast cancer |
| Q79448439 | Chemoprevention of breast cancer with selective oestrogen-receptor modulators |
| Q36883674 | Chemoprevention strategies 2006. |
| Q46203992 | Chemoprevention: drug pricing and mortality: the case of tamoxifen. |
| Q35648512 | Clinical infrastructures to support proteomic studies of tissue and fluids in breast cancer |
| Q73666921 | Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy |
| Q35554561 | Coagulopathic complications in breast cancer |
| Q59288489 | Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial |
| Q33808014 | Consumption of sweet foods and mammographic breast density: a cross-sectional study |
| Q45168977 | Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene |
| Q33599463 | Current strategies for the prevention of breast cancer |
| Q37355588 | Decreased risk of breast cancer associated with oral bisphosphonate therapy |
| Q36206691 | Differential control of growth, apoptotic activity, and gene expression in human breast cancer cells by extracts derived from medicinal herbs Zingiber officinale. |
| Q34732145 | Do physicians tailor their recommendations for breast cancer risk reduction based on patient's risk? |
| Q80984932 | Does tamoxifen prophylaxis for breast cancer provide long-term prevention? |
| Q24794407 | Ductal approaches to assessment and management of women at high risk for developing breast cancer |
| Q37900543 | Ductal carcinoma in situ (DCIS) of the breast: perspectives on biology and controversies in current management |
| Q28270358 | Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes |
| Q37509637 | Ductal carcinoma in situ: risk factors and impact of screening. |
| Q24813532 | Early stopping of clinical trials |
| Q47161842 | Eco-Friendly Formulated Zinc Oxide Nanoparticles: Induction of Cell Cycle Arrest and Apoptosis in the MCF-7 Cancer Cell Line |
| Q50460101 | Economic evaluation of using a genetic test to direct breast cancer chemoprevention in white women with a previous breast biopsy. |
| Q53408150 | Effects of Tamoxifen and oestrogen on histology and radiographic density in high and low mammographic density human breast tissues maintained in murine tissue engineering chambers. |
| Q35052293 | Effects of low-dose tamoxifen on breast cancer biomarkers Ki-67, estrogen and progesterone receptors |
| Q35024239 | Effects of tamoxifen versus raloxifene on retinal capillary endothelial cell proliferation |
| Q36383775 | Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women |
| Q35612319 | Endocrine prevention of breast cancer using selective oestrogen receptor modulators (SORMs). |
| Q57108564 | Endocrine therapy for breast cancer in the primary care setting |
| Q38753738 | Endocrine therapy for breast cancer prevention in high-risk women: clinical and economic considerations |
| Q37385376 | Endocrine therapy for the treatment of postmenopausal women with breast cancer |
| Q44620737 | Endometrial surveillance of women on tamoxifen |
| Q36993383 | Estrogen receptor modulators and down regulators: optimal use in postmenopausal women with breast cancer |
| Q52720179 | Estrogenicity of essential oils is not required to relieve symptoms of urogenital atrophy in breast cancer survivors. |
| Q33967068 | European Code Against Cancer and scientific justification: third version (2003). |
| Q35441054 | Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme |
| Q27028211 | Exemestane for breast cancer prevention: a critical shift? |
| Q37597968 | Extraction of tamoxifen and its metabolites from formalin-fixed, paraffin-embedded tissues: an innovative quantitation method using liquid chromatography and tandem mass spectrometry |
| Q33965106 | Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer |
| Q51627211 | Familial breast cancer. |
| Q36172491 | Gaining control over breast cancer risk: Transforming vulnerability, uncertainty, and the future through clinical trial participation - a qualitative study |
| Q35552631 | Genetics and the Management of Women at High Risk for Breast Cancer |
| Q35775223 | Genetics of breast cancer: a topic in evolution |
| Q22064616 | Genome-wide association studies and the clinic: a focus on breast cancer |
| Q39631317 | Ginsenoside Rh2 induces Bcl-2 family proteins-mediated apoptosis in vitro and in xenografts in vivo models |
| Q37349463 | Ginsenoside Rh2-mediated G1 phase cell cycle arrest in human breast cancer cells is caused by p15 Ink4B and p27 Kip1-dependent inhibition of cyclin-dependent kinases |
| Q36959818 | High-risk benign breast lesions: current strategies in management |
| Q34953339 | Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategies |
| Q36963393 | Hormonal therapies in young breast cancer patients: when, what and for how long? |
| Q35852845 | Hormones and pregnancy: thromboembolic risks for women |
| Q36613647 | Impact of familial risk factors on management and survival of early-onset breast cancer: a population-based study |
| Q36258270 | Impact of preventive therapy on the risk of breast cancer among women with benign breast disease. |
| Q37332345 | Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS). |
| Q37355945 | In vitro human skin permeation of endoxifen: potential for local transdermal therapy for primary prevention and carcinoma in situ of the breast |
| Q38778524 | Incorporating Biomarkers in Studies of Chemoprevention |
| Q33817215 | Inhibition of human breast cancer xenograft growth by cruciferous vegetable constituent benzyl isothiocyanate |
| Q36695313 | Interaction of dense breast patterns with other breast cancer risk factors in a case-control study |
| Q92463752 | Interpretation of breast cancer screening guideline for Chinese women |
| Q30975478 | Interpreting quality-of-life data from the SOFT and TEXT trials |
| Q96302976 | Key steps for effective breast cancer prevention |
| Q34009224 | Knowledge and accuracy of perceived personal risk in underserved women who are at increased risk of breast cancer |
| Q35000324 | Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I. |
| Q35678139 | Management issues for elderly patients with breast cancer |
| Q36906736 | Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club |
| Q36806140 | Managing oral chemotherapy: the healthcare practitioner's role |
| Q28086915 | Medical prevention of breast cancer |
| Q34742590 | Meta-analysis of vascular and neoplastic events associated with tamoxifen |
| Q26797207 | Molecular cancer prevention: Current status and future directions |
| Q37402403 | Molecular targets for cancer chemoprevention |
| Q38326758 | Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. |
| Q60946525 | Mutations and Breast Cancer Prevention |
| Q36616900 | Myocardial infarction risk and tamoxifen therapy for breast cancer |
| Q36957733 | New perspectives of curcumin in cancer prevention. |
| Q33456377 | Next-generation transcriptome sequencing of the premenopausal breast epithelium using specimens from a normal human breast tissue bank. |
| Q35572443 | Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways |
| Q30936399 | Ongoing data from the breast cancer prevention trials: opportunity for breast cancer risk reduction |
| Q30592796 | Optical imaging correlates with magnetic resonance imaging breast density and reveals composition changes during neoadjuvant chemotherapy |
| Q35057371 | Overview of the main outcomes in breast-cancer prevention trials |
| Q38702563 | Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I). |
| Q35227793 | Participation of Asian-American women in cancer chemoprevention research: physician perspectives |
| Q96577047 | Personalized early detection and prevention of breast cancer: ENVISION consensus statement |
| Q27006783 | Pharmacogenomics of breast cancer therapy: an update |
| Q94526353 | Pharmacological cancer treatment and venous thromboembolism risk |
| Q35601587 | Pharmacological prevention of breast cancer: quo vadis? |
| Q28072526 | Physician and Patient Barriers to Breast Cancer Preventive Therapy |
| Q36638994 | Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up |
| Q24198028 | Postoperative tamoxifen for ductal carcinoma in situ |
| Q92281922 | Potential Mechanisms of Age Acceleration Caused by Estrogen Deprivation: Do Endocrine Therapies Carry the Same Risks? |
| Q64116481 | Prediction of reader estimates of mammographic density using convolutional neural networks |
| Q46429199 | Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction. |
| Q34393592 | Preventative therapies for healthy women at high risk of breast cancer |
| Q51843372 | Preventing invasive breast cancer using endocrine therapy. |
| Q37798835 | Prevention of breast cancer (Part II): risk reduction strategies |
| Q28390064 | Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk |
| Q35572427 | Prevention of breast cancer using SERMs and aromatase inhibitors |
| Q36654338 | Prevention of breast cancer: current state of the science and future opportunities |
| Q37480364 | Prevention of mammary carcinogenesis in MMTV-neu mice by cruciferous vegetable constituent benzyl isothiocyanate |
| Q37608402 | Preventive oncology in the postmenopausal woman. |
| Q54484341 | Preventive therapy for breast cancer. |
| Q39035276 | Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma |
| Q35687696 | Progress in chemoprevention of breast cancer |
| Q59349295 | Progress in preventive therapy for cancer: a reminiscence and personal viewpoint |
| Q79954098 | Pulmonary embolism |
| Q35843668 | Raloxifene and its role in breast cancer prevention |
| Q38825454 | Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women |
| Q44548869 | Raloxifene inhibits estrogen-induced up-regulation of telomerase activity in a human breast cancer cell line |
| Q39937328 | Raloxifene, a selective estrogen receptor modulator, induces mitochondria-mediated apoptosis in human endometrial carcinoma cells |
| Q35962026 | Recognizing BRCA gene mutation risk subsequent to breast cancer diagnosis in southwestern Ontario |
| Q51760105 | Relations of omega-3 and omega-6 intake with mammographic breast density. |
| Q42372951 | Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials. |
| Q36090022 | Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial. |
| Q37176019 | Risk assessment model for invasive breast cancer in Hong Kong women. |
| Q36051449 | Risk assessment: controversies and management of moderate- to high-risk individuals |
| Q61797741 | Risk prediction for breast Cancer in Han Chinese women based on a cause-specific Hazard model |
| Q92734170 | Risk versus Benefit of Chemoprevention among Raloxifene and Tamoxifen Users with a Family History of Breast Cancer |
| Q34974865 | Risk-benefit profiles of women using tamoxifen for chemoprevention |
| Q91590902 | Risk-reducing medications for primary breast cancer: a network meta-analysis |
| Q36378855 | Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention |
| Q36794420 | SERMs for the treatment and prevention of breast cancer |
| Q34490225 | Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast |
| Q38455538 | Selective estrogen receptor modulators in clinical practice: a safety overview |
| Q30620889 | Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data |
| Q26823102 | Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis |
| Q35911820 | Should tamoxifen be used in breast cancer prevention? |
| Q36633831 | Skeletal complications of breast cancer therapies |
| Q39033804 | Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy |
| Q26782494 | Statistical controversies in clinical research: long-term follow-up of clinical trials in cancer |
| Q36578211 | Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells |
| Q38150222 | Suitable trial designs and cohorts for preventive breast cancer agents |
| Q37671187 | Systemic Therapy for Early-Stage Breast Cancer: What the Plastic Surgeon Should Know |
| Q44413882 | Tamoxifen administration and metabolism in nude mice and nude rats |
| Q34044998 | Tamoxifen and flaxseed alter angiogenesis regulators in normal human breast tissue in vivo |
| Q34629307 | Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump |
| Q44280781 | Tamoxifen for breast-cancer prevention |
| Q45833605 | Tamoxifen for breast-cancer prevention. |
| Q36634556 | Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial |
| Q45944471 | Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. |
| Q91100202 | Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis |
| Q59288218 | Tamoxifen-Induced Reduction in Mammographic Density and Breast Cancer Risk Reduction: A Nested Case-Control Study |
| Q33404691 | Tamoxifen-associated Budd-Chiari syndrome complicated by heparin-induced thrombocytopenia and thrombosis: a case report and literature review |
| Q34180688 | Tamoxifen: a most unlikely pioneering medicine |
| Q37190825 | Targeted therapy for breast cancer prevention |
| Q34272044 | Targeting HER2 in breast cancer: overview of long-term experience |
| Q28397456 | Targeting the estrogen pathway for the treatment and prevention of lung cancer |
| Q37357294 | The NSABP Study of Tamoxifen and Raloxifene (STAR) trial |
| Q28217652 | The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial |
| Q44713329 | The benefits and costs of tamoxifen for breast cancer prevention |
| Q36150559 | The cerebrovascular risks associated with tamoxifen use. |
| Q24802837 | The diagnosis and management of pre-invasive breast disease Problems associated with management of pre-invasive lesions |
| Q34315816 | The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators |
| Q26822900 | The failure of cancer chemoprevention |
| Q36646603 | The influence of tamoxifen treatment on the oestrogen receptor in metachronous contralateral breast cancer |
| Q45076127 | The management of ductal carcinoma in situ in North America and Europe. Results of a survey |
| Q35911530 | The prevention of invasive breast carcinoma |
| Q37602314 | The rationale and potential of cancer chemoprevention with special emphasis on breast cancer |
| Q35217988 | The risks and benefits of hormonal replacement therapy in healthy women and in breast cancer survivors |
| Q35069353 | The role of aromatase inhibitors in early breast cancer |
| Q34590315 | The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene |
| Q38703578 | The selective estrogen receptor modulators in breast cancer prevention |
| Q53328453 | The theory of the sick breast lobe and the possible consequences. |
| Q35543467 | Thromboembolic Events in the Cancer Patient |
| Q91979030 | Thrombotic Risk from Chemotherapy and Other Cancer Therapies |
| Q53837780 | Tissue selective estrogen complex (TSEC): a review. |
| Q24806501 | Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones |
| Q48039896 | Treatment-related risk factors for arm lymphedema among long-term breast cancer survivors |
| Q34110074 | Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer |
| Q37355998 | Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women |
| Q36947842 | Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer |
| Q37165630 | Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010 |
| Q80246376 | Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening |
| Q37400617 | Validity assessment of the Breast Cancer Risk Reduction Health Belief scale |
| Q33408419 | Venous access catheter-related thrombosis in patients with cancer |
| Q35728779 | Venous thromboembolism and malignancy |
| Q47309977 | Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer |
| Q34828174 | Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo |
| Q34253370 | Withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells |
| Q34929281 | Women's views on chemoprevention of breast cancer: qualitative study. |
| Q33895595 | p53-Independent apoptosis by benzyl isothiocyanate in human breast cancer cells is mediated by suppression of XIAP expression |
Search more.